US equities |
MU $1,084.58 ▲+3.73% SNDK $1,724.64 ▲+3.87% NVDA $236.80 ▼-1.02% AMD $642.74 ▼-1.03% SPCX $167.40 ▼-2.63% INTC $112.89 ▲+0.35% TSLA $376.04 ▼-1.22% AAPL $335.62 ▲+0.60%
FinancialContent

Instinct Bio Technical Company Holdings Inc. - Common stock (NQ:BIOT)

0.3898 +0.0168 (+4.50%)
Delayed Quote Updated: 1:00 PM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Instinct Bio Technical Company Holdings Inc. - Common stock

News headline image
BIOT Named Authorized Representative for IN01 Cancer Immunotherapy in Japan and China
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Instinct Bio Receives Nasdaq Notifications Regarding Minimum Bid Requirement and Minimum Market Value of Listed Securities and Publicly Held Shares
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
INSTINCT BIO Provides Operational Update on Indonesia Growth Platform and Product Development Initiatives
Follow-up to the Company’s July 29, July 30 and August 10, 2026 announcements 
From Instinct Bio Technical Company Holdings Inc.
Via GlobeNewswire
News headline image
Instinct Bio Announces Strategic Collaboration with PT PARVA CANDELA to Develop Cosmetics Business in Indonesia
From Instinct Bio Technical Company Holdings Inc.
Via GlobeNewswire
News headline image
Instinct Bio Announces Strategic Collaboration With INVITRX to Expand GENREVER Into U.S. and Advance Indonesia Regenerative Medicine Initiatives
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Blade Therapeutics to Participate in “Drug Development in Pulmonary Medicine” Panel Discussion at 2022 BTIG Biotechnology Conference
From Blade Therapeutics, Inc.
Via Business Wire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
Good morning! We're preparing for another busy day of trading with a breakdown of the biggest pre-market stock movers for Friday! 
Via InvestorPlace
News headline image
Blade Therapeutics Presents Preclinical Data Highlighting Differentiating Characteristics of Cudetaxestat at the American Thoracic Society 2022 International Conference
From Blade Therapeutics, Inc.
Via Business Wire
News headline image
Blade Therapeutics Presents Data from Phase 1 and Preclinical Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference
From Blade Therapeutics, Inc.
Via Business Wire
News headline image
Blade Therapeutics Announces Feedback from FDA on End-of-Phase 1 Data Package
From Blade Therapeutics, Inc.
Via Business Wire
News headline image
Blade Therapeutics to Present Data from Preclinical and Phase 1 Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference
From Blade Therapeutics, Inc.
Via Business Wire
News headline image
Blade Therapeutics Announces Successful Completion of Phase 1 Clinical Study that Evaluated Co-Administration of Cudetaxestat with Either of Two Approved Therapies for Idiopathic Pulmonary Fibrosis
From Blade Therapeutics, Inc.
Via Business Wire